AtriCure Inc

AtriCure's fair value price target has shifted from about US$51.67 to about US$54.89, reflecting modest fine tuning in analyst models rather than a wholesale reset. BTIG raised its AtriCure price target to US$55 from US$45, pointing to the new STS Quality Metric, which it thinks could support greater use of the EnCompass Clamp in U.S. surgery patients with preoperative atrial fibrillation, and noting that only about 35% of atrial fibrillation patients undergoing cardiac surgery in the U.S. currently receive a surgical ablation. BTIG models potential upside to AtriCure's U.S. Open Ablation revenue of US$10m to US$25m in 2027 and US$20m to US$55m in 2028 compared with its prior forecasts. UBS keeps a Buy rating on AtriCure alongside a revised price target of US$50 from US$55, citing business growth excluding MIS as support for what it describes as sustainable double digit top line expansion. Freedom Capital downgraded AtriCure to Hold from Buy and lifted its target to US$57 from US$43, expecting BoX-NoAF POAF data in Q2 2027 to be positive but flagging that earlier supportive data carries caveats, which it thinks reduces the margin for error if results or execution fall short of expectations. Revenue growth assumptions are broadly steady, moving from about 12.33% to about 12.35%, net profit margin expectations remain around 4.55%, future P/E has moved from about 94.5x to about 101.3x, and the discount rate is broadly unchanged, moving from about 7.52% to about 7.55%.

The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.

AtriCure reported second-quarter fiscal 2026 results that beat consensus estimates, with revenue of $153.6 million and adjusted earnings per share of $0.18. Revenue exceeded expectations by $1.79 million and adjusted EPS surpassed forecasts by $0.16, an 800% beat. The company swung to a net income of $9 million from a net loss of $6.2 million a year earlier, while adjusted EBITDA reached $27 million. Gross margin expanded 270 basis points to 77.2%, driven by product innovation, geographic mix, and efficiencies. Management raised full-year revenue guidance to $602 million to $610 million and adjusted EBITDA guidance to $85 million to $89 million, with EPS expected between $0.05 and $0.13.

AtriCure shares surged 6.2% to close at $28.80 in the last trading session on heavy volume. The rally followed the company's presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its target of reaching $1 billion in revenue by 2030 and highlighted the market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials. Investors also reacted to news of accelerated enrollment in the BoxX-NoAF trial, which could significantly broaden the company's addressable market if outcomes are positive. The stock currently carries a Zacks Rank of 3, or Hold.